^
Association details:
| Biomarker: | EGFR-SEPTIN14 rearrangement |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing
Excerpt:
A next-generation sequencing (NGS) analysis of the tumor biopsy specimen revealed a novel EGFR-SEPTIN14 rearrangement...the patient underwent treatment with orally administered icotinib (125 mg/twice daily) in February 2016. After 1 month, a chest CT scan showed a decrease in tumor size (Fig. 1B). According to the Response Evaluation Criteria in Solid Tumors guidelines, the patient was considered to have a partial response to icotinib...the disease has remained stable and the patient has been continuing treatment with icotinib.
DOI:
10.1016/j.jtho.2019.03.031
